When the COVID-19 pandemic struck earlier this year, clinical trials at medical centers around the world slowed enrollment or placed trial activities on hold.
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated.
The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from,…
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in…
A recent rise in litigation linking cosmetic talc with mesothelioma and lung cancer will continue throughout 2020, despite companies abandoning the product in…
